Related references
Note: Only part of the references are listed.Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Tomoya Yokota
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function
Douglas W. McMillin et al.
BLOOD (2012)
e-Blood Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma
Richard W. J. Groen et al.
BLOOD (2012)
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy
Marta Chesi et al.
BLOOD (2012)
Translational approaches targeting the p53 pathway for anti-cancer therapy
Frank Essmann et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
The metastatic niche and stromal progression
Jonathan P. Sleeman
CANCER AND METASTASIS REVIEWS (2012)
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Taru Muranen et al.
CANCER CELL (2012)
Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
Elizabeth S. Nakasone et al.
CANCER CELL (2012)
New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
Giuseppe Curigliano
CANCER TREATMENT REVIEWS (2012)
Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates
C. Wilson et al.
CANCER TREATMENT REVIEWS (2012)
Current advances in humanized mouse models
Ryoji Ito et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2012)
Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Eveline M. Dijkgraaf et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Mallika Singh et al.
JOURNAL OF PATHOLOGY (2012)
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R. Smith et al.
LANCET (2012)
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts
Y. Tabe et al.
LEUKEMIA (2012)
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett et al.
NATURE (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
Mallika Singh et al.
NATURE BIOTECHNOLOGY (2012)
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia
Wan Zhang et al.
NATURE CELL BIOLOGY (2012)
Genomically humanized mice: technologies and promises
Anny Devoy et al.
NATURE REVIEWS GENETICS (2012)
Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
Ayalew Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Paraneoplastic Thrombocytosis in Ovarian Cancer
Rebecca L. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bone Marrow Stromal Cells Modulate Mouse ENT1 Activity and Protect Leukemia Cells from Cytarabine Induced Apoptosis
Patricia Macanas-Pirard et al.
PLOS ONE (2012)
Functional genomics identifies therapeutic targets for MYC-driven cancer
Masafumi Toyoshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
Lapatinib and Obatoclax Kill Tumor Cells through Blockade of ERBB1/3/4 and through Inhibition of BCL-xL and MCL-1
Nichola Cruickshanks et al.
MOLECULAR PHARMACOLOGY (2012)
Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis
Conor C. Lynch
BONE (2011)
Loss or Inhibition of Stromal-Derived PIGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia
Thomas Schmidt et al.
CANCER CELL (2011)
The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Ning Li et al.
CANCER CELL (2011)
Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
Taghi Manshouri et al.
CANCER RESEARCH (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Immune microenvironments in solid tumors: new targets for therapy
Stephen L. Shiao et al.
GENES & DEVELOPMENT (2011)
Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype
Michael F. Emmons et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance
Edward H. Flach et al.
MOLECULAR PHARMACEUTICS (2011)
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Jonathan W. Wojtkowiak et al.
MOLECULAR PHARMACEUTICS (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Histamine restricts cancer: nothing to sneeze at
Brian Ruffell et al.
NATURE MEDICINE (2011)
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
Mina J. Bissell et al.
NATURE MEDICINE (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Antibodies in oncology
Vinochani Pillay et al.
NEW BIOTECHNOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation
Douglas W. McMillin et al.
PLOS ONE (2011)
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Jean-Pierre Gillet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer
Hiu Wing Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Triona Ni Chonghaile et al.
SCIENCE (2011)
Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Maria-Christina Kastrinaki et al.
CURRENT STEM CELL RESEARCH & THERAPY (2011)
Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Govardhanan Nagaiah et al.
JOURNAL OF ONCOLOGY (2011)
Mouse models of advanced spontaneous metastasis for experimental therapeutics
Giulio Francia et al.
NATURE REVIEWS CANCER (2011)
The microenvironment in breast cancer progression: biology and implications for treatment
Andrew E. Place et al.
BREAST CANCER RESEARCH (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
David G. DeNardo et al.
CANCER AND METASTASIS REVIEWS (2010)
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
Norman Chan et al.
CANCER RESEARCH (2010)
The COXEN Principle: Translating Signatures of In vitro Chemosensitivity into Tools for Clinical Outcome Prediction and Drug Discovery in Cancer
Steven C. Smith et al.
CANCER RESEARCH (2010)
Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease
Frits van Rhee et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer and Inflammation: Promise for Biologic Therapy
Sandra Demaria et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors
Ellen Weisberg et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line
Wang Guo-Bao et al.
LEUKEMIA & LYMPHOMA (2010)
How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection
Cristina Scielzo et al.
LEUKEMIA & LYMPHOMA (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
Douglas W. McMillin et al.
NATURE MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment
Kenneth E. Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Third-Generation Tyrosine Kinase Inhibitors and Beyond
Alfonso Quintas-Cardama et al.
SEMINARS IN HEMATOLOGY (2010)
Examining the Metastatic Niche: Targeting the Microenvironment
Theresa Guise
SEMINARS IN ONCOLOGY (2010)
Effects of Bone Marrow Stromal Cells and Umbilical Cord Blood-Derived Stromal Cells on Daunorubicin-Resistant Residual Jurkat Cells
X. Liang et al.
TRANSPLANTATION PROCEEDINGS (2010)
Does tumour dormancy offer a therapeutic target?
Paul E. Goss et al.
NATURE REVIEWS CANCER (2010)
T Cell Activation
Jennifer E. Smith-Garvin et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
Joseph M. Negri et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation
Ronald R. Gomes et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model
Cigall Kadoch et al.
CLINICAL CANCER RESEARCH (2009)
Revisiting the seed and soil in cancer metastasis
Martin Mendoza et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases
Jens Hoffmann et al.
NEURO-ONCOLOGY (2009)
Integrins - The keys to unlocking angiogenesis
Rita Silva et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine
A. C. Dudley et al.
BRITISH JOURNAL OF CANCER (2008)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi et al.
CANCER CELL (2008)
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis
William Cruz-Munoz et al.
CANCER RESEARCH (2008)
The state of innovation in drug development
I. Kola
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
Nadine N. Bewry et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival
Bijan Moshaver et al.
LEUKEMIA & LYMPHOMA (2008)
Protein therapeutics: A summary and pharmacological classification
Benjamin Leader et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers
Nancy Dumont et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment
M. C. Stubbs et al.
LEUKEMIA (2008)
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub et al.
NATURE (2007)
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells
Ellen Weisberg et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment
Marina Brama et al.
ENDOCRINE-RELATED CANCER (2007)
Humanized mice in translational biomedical research
Leonard D. Shultz et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Economics of new oncology drug development
Joseph A. DiMasi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer metastasis:: Building a framework
Gaorav P. Gupta et al.
CELL (2006)
Mutations in the NF-κB signaling pathway:: implications for human disease
G. Courtois et al.
ONCOGENE (2006)
Tumor metastasis: mechanistic insights and clinical challenges
Patricia S. Steeg
NATURE MEDICINE (2006)
Role of VAD in the initial treatment of multiple myeloma
SW Lane et al.
BLOOD (2005)
Distinct epigenetic changes in the stromal cells of breast cancers
M Hu et al.
NATURE GENETICS (2005)
A mouse mode of human breast cancer metastasis to human bone
C Kuperwasser et al.
CANCER RESEARCH (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
Implantation mechanisms: insights from the sheep
TE Spencer et al.
REPRODUCTION (2004)
Stromal fibroblasts in cancer initiation and progression
NA Bhowmick et al.
NATURE (2004)
Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model
I Brigger et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
J Debnath et al.
METHODS (2003)
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms
Y Nefedova et al.
LEUKEMIA (2003)
The organizing principle: microenvironmental influences in the normal and malignant breast
MJ Bissell et al.
DIFFERENTIATION (2002)
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
T Hideshima et al.
NATURE REVIEWS CANCER (2002)
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells:: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions
O Peyruchaud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Tumour-stromal interactions - Integrins and cell adhesions as modulators of mammary cell survival and transformation
MA Chrenek et al.
BREAST CANCER RESEARCH (2001)
Share Paper
